CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Candesartan Cilexetil And Hydrochlorothiazide, and when can generic versions of Candesartan Cilexetil And Hydrochlorothiazide launch?
Candesartan Cilexetil And Hydrochlorothiazide is a drug marketed by Apotex Inc, Dr Reddys Labs Ltd, Macleods Pharms Ltd, Mylan, Prinston Inc, and Zydus Lifesciences. and is included in six NDAs.
The generic ingredient in CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE is candesartan cilexetil; hydrochlorothiazide. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the candesartan cilexetil; hydrochlorothiazide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Candesartan Cilexetil And Hydrochlorothiazide
A generic version of CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE was approved as candesartan cilexetil; hydrochlorothiazide by MYLAN on December 4th, 2012.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE?
- What are the global sales for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE?
- What is Average Wholesale Price for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE?
Summary for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 6 |
| Finished Product Suppliers / Packagers: | 4 |
| Clinical Trials: | 6 |
| What excipients (inactive ingredients) are in CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE? | CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE excipients list |
| DailyMed Link: | CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE at DailyMed |
Recent Clinical Trials for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| GlaxoSmithKline | Phase 1 |
| Takeda | Phase 4 |
| Takeda |
See all CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE clinical trials
Pharmacology for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
| Drug Class | Angiotensin 2 Receptor Blocker Thiazide Diuretic |
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
| Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apotex Inc | CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE | candesartan cilexetil; hydrochlorothiazide | TABLET;ORAL | 202884-001 | Dec 4, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zydus Lifesciences | CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE | candesartan cilexetil; hydrochlorothiazide | TABLET;ORAL | 203466-003 | Nov 27, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Macleods Pharms Ltd | CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE | candesartan cilexetil; hydrochlorothiazide | TABLET;ORAL | 204100-001 | Feb 27, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
